Full-Time
Chemical Process Engineer
Posted on 1/24/2026
Agilent Technologies
10,001+ employees
Provides eProcurement automation and hosted catalogs
Compensation Overview
$97.9k - $153k/yr
Company Does Not Provide H1B Sponsorship
Wilmington, DE, USA
In Person
 Process Engineering |
|---|
- Bachelor’s or Master’s degree in Chemical Engineering, Chemistry, or a related field.
- 4+ years of proven ability in chemical manufacturing or process engineering.
- Strong analytical skills with experience in root cause analysis and process optimization.
- Proficiency in data analysis tools and reporting systems.
- Excellent communication and teamwork skills across multi-functional teams.
- Familiarity with ERP systems and manufacturing documentation.
- Lead end-to-end chemical manufacturing for HPLC product lines, ensuring consistent quality and output.
- Analyze process and quality control data to identify root causes and implement corrective actions.
- Improve process control, equipment performance, and production efficiency through data-driven solutions.
- Develop and maintain SOPs to ensure repeatable and well-documented processes.
- Apply lean and continuous improvement methodologies to reduce cost and improve quality.
- Evaluate and implement new equipment or process changes to support business growth and supply chain optimization.
- Collaborate with procurement and suppliers to ensure material quality, cost-effectiveness, and timely delivery.
- Identify and qualify alternative materials to support production continuity.
- Provide input on new product introductions to ensure manufacturability and alignment with global supply chain requirements.
- Occasionally lead ERP data, including bill of materials and routing.
- Experience in HPLC or analytical chemistry applications.
- Knowledge of ISO 9001, cGMP, and REACH regulations.
- Certification in Lean Six Sigma or equivalent process improvement methodologies.
- Experience with chemical safety standards and hazardous materials handling.
- Familiarity with regulatory compliance for chemical manufacturing (e.g., OSHA, EPA).
Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.
Company Size
10,001+
Company Stage
IPO
Headquarters
Santa Clara, California
Founded
1999
Simplify's Take
What believers are saying
- Eight FDA-approved PD-L1 IHC 22C3 pharmDx indications drive companion diagnostics revenue.
- AI-enabled imaging software differentiates Agilent amid sector vulnerability to funding fluctuations.
- Analysts project $8.6 billion revenue and $2 billion earnings by 2029.
What critics are saying
- Biocare integration failure destroys $200–300M expected value within 12–24 months.
- Supreme Court CRISPR patent denial enables competitors to develop rival enrichment workflows.
- Research funding contraction cuts recurring consumables revenue $200–600M annually within 12–18 months.
What makes Agilent Technologies unique
- Biocare Medical acquisition adds 300+ specialized antibodies with double-digit growth since 2021.
- BioTek Cytation 9 combines high-content imaging with automation for research labs.
- Oxford Nanopore partnership enables structural variant analysis and methylation profiling applications.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Performance Bonus
Stock Options
Company News
Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.
Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.
Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.
Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t
Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction